QIAGEN has expanded its ongoing research collaboration with Sysmex to focus more closely on companion diagnostics. Financial and other details of the new agreement were undisclosed.

During the partnership, Sysmex will integrate QIAGEN’s assays in clinical trials provided to pharmaceutical firms and research institutions globally. This collaboration will leverage Sysmex’s laboratories worldwide, and QIAGEN's services will also gain global support. Sysmex will accelerate the development of enhanced testing and diagnostic technologies. 

Analyst QuickTake: The strategic alliance between QIAGEN and Sysmex was established in July 2021 . The collaboration was focused on the development and commercialization of cancer companion diagnostics, leveraging QIAGEN’s expertise in this field and Sysmex’s Plasma-Safe-SeqS technology for next-generation sequencing (NGS). The companies aimed to collaborate with pharmaceutical companies to develop oncology therapeutics and to promote early clinical adoption of its ultra-sensitive liquid biopsy companion diagnostics.